Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Emtricitabin + Rilpivirin + Tenofovir disoproxil fumarat, ATC J05AR08 für die Zeit 01.09.2026 - 31.08.2028

Section 130a(8) of the German Social Code Book V (SGB V) enables health insurance companies and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance. With regard to the relevant legal provisions for the awarding of public contracts, a regular process of substance-related, formal tendering procedures is conducted by DAK-Gesundheit in accordance with the regulations of Part 4 of the German Competition Act (GWB). For medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned active substance Emtricitabin + Rilpivirin + Tenofovir disoproxil fumarat, ATC J05AR08, DAK-Gesundheit intends to conclude medicine discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine discount contracts. A discount contract under the approval model for the aforementioned active substance will come into effect for the first time on 01.09.2026 and will end on 31.08.2028. It will end automatically with the entry into force of the exclusive contract, regardless.